Delivering continued growth

We are delighted to report on another outstanding
year for Abcam. We continue to deliver sustained
growth across the entire portfolio, achieving a 17.1%
increase in revenue this year. In addition we have
also delivered significant progress with the
introduction of our new product ranges.

Abcam has become a market
leader in antibodies through
constant innovation, commitment
to our customers, and nurturing
employee excellence.
We
deliver

We are
delighted to
report on another
outstanding year.

Revenue (£m)

83.3

Profit

before tax (£m)

32.1

We will deliver growth by: